Physician profile
Jonathan Patrick Grady
NPI 1386838563
$217,305.20
in general payments reported to CMS, 2019-2025
30 companies · $57K in 2025
The $57K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $459 · 2021: $1,329 · 2022: $20K · 2023: $50K · 2024: $88K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Travel and Lodging: $34K · Food and Beverage: $8,884 · Consulting Fee: $288 · Gift: $108 · Education: $28.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151,175.00 |
| Travel and Lodging | $34,073.31 |
| Food and Beverage | $8,884.24 |
| Consulting Fee | $287.50 |
| Gift | $108.23 |
| Education | $28.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $204,986.01 | 2022-2025 | |
| Allergan, INC. | $6,151.83 | 2019-2022 | |
| Beaver-Visitec International, INC. | $1,697.69 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $885.37 | 2019-2025 | Cequa |
| Alcon Vision LLC | $586.87 | 2019-2025 | Rocklatan, Rhopressa, Hydrus Microstent |
| Harrow Eye, LLC | $383.11 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $303.47 | 2022-2024 | Miebo, Xiidra, Envista Mx60 Iol |
| Tarsus Pharmaceuticals, INC. | $295.68 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $284.81 | 2019-2023 | |
| Carl Zeiss Meditec USA, INC. | $212.89 | 2022 | |
| Sight Sciences, INC. | $157.79 | 2022-2025 | Omni Surgical System |
| New World Medical,INC. | $143.18 | 2023 | |
| Oyster Point Pharma, INC. | $123.65 | 2022-2024 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $120.52 | 2024-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Haag-Streit USA, INC. | $119.30 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.94 | 2019 | |
| Aerie Pharmaceuticals, INC. | $111.94 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $108.77 | 2019-2024 | Veritas Vision System |
| Kala Pharmaceuticals, INC. | $94.93 | 2021-2022 | |
| Dompe US, INC. | $72.10 | 2019-2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $62.00 | 2019-2023 | Acuvue |
| Ivantis, INC | $47.35 | 2021 | |
| Rxsight INC | $43.11 | 2021-2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Shire North American Group INC | $24.84 | 2019 | |
| Biotissue Holdings INC. | $24.82 | 2021 | |
| Mallinckrodt Hospital Products INC. | $22.15 | 2022 | |
| Thea Pharma INC. | $21.76 | 2023 | Iyuzeh |
| Amgen INC. | $20.58 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $18.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Grady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.